Ohio State Navbar

Sign In

RSS Feed Regenerative Medicine News

FDA Approves Stemedica Phase II Clinical Trial for Acute Myocardial Infarction with Ischemia Tolerant Mesenchymal Stem Cells 


October 2, 2012 - (Stemedica) - "Stemedica Cell Technologies, Inc., a leader in adult allogeneic stem cell manufacturing, research and development, announced today that the U.S. Food and Drug Administration (FDA) approved its application for an Investigational New Drug (IND) to assess the clinical effects of Stemedyne-MSC (Stemedica’s human bone marrow-derived ischemia tolerant mesenchymal cells) in subjects with a myocardial infarct."  Read Full Article


Posted on 8-Oct-12 by Gallerno, Jacob
Tags: Science and Industry News
Trackback Url  |  Link to this post | Bookmark this post with: